Arcus Biosciences, Inc. (RCUS)

NYSE Pharmaceutical Pharmaceutical Preparations SIC: 2834
D
Pipeline Grade

Financial Position (from SEC Filings)

$201.0M
Cash & Equivalents
$138.0M
Quarterly Burn Rate
4 mo
Est. Cash Runway
$3,015M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

No upcoming catalysts detected for this company.

Active Clinical Trials (1)

NCT #TitlePhaseStatusEnrollment
NCT03821246 Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy PHASE2 Recruiting 68

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for RCUS.

SEC EDGAR Filings

All SEC filings for Arcus Biosciences, Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.